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Abstract 
Bi-functional shRNA (bi-shRNA), a novel RNA interference (RNAi) effector 
platform targeting PDX-1 utilizing a systemic DOTAP-Cholesterol delivery 
vehicle, was studied in three mouse models of progressive pancreatic neoplasia. 
Species-specific bi-functional PDX-1 shRNA (bi-shRNAPDX-1) lipoplexes inhibited 
insulin expression and secretion while also substantially inhibiting proliferation of 
mouse and human cell lines via disruption of cell cycle proteins in vitro. Three 
cycles of either bi-shRNAmousePDX-1 or shRNAmousePDX-1 lipoplexes administered 
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intravenously prevented death from hyperinsulinemia and hypoglycemia in a 
lethal insulinoma mouse model. Three cycles of shRNAmousePDX-1 lipoplexes 
reversed hyperinsulinemia and hypoglycemia in an immune-competent mouse 
model of pancreatic neoplasia. Moreover, three cycles of the bi-shRNAhumanPDX-1 
lipoplexes resulted in near complete ablation of tumor volume and considerably 
improved survival in a human PANC-1 implanted SCID-mouse model. Human 
pancreatic neoplasia specimens also stained strongly for PDX-1 expression. 
Together, these data support the clinical development of a novel therapeutic 
strategy using systemic bi-shRNAPDX-1 lipoplexes against pancreatic neoplasia.   
 
 
Pancreatic and duodenal homeobox-1 (PDX-1) is a transcription factor that plays 
a critical role in regulating embryologic pancreas development as well as in 
insulin expression and islet maintenance in the adult pancreas1-4. PDX-1 has 
recently been shown to play a significant role in islet cell neoplasia and 
pancreatic cancer5-11.  PDX-1 knockout is lethal in mice and mutation of PDX-1 
leads to mature onset of diabetes of the young (MODY subtype IV) in mice and 
human patients12,13. Persistent overexpression of PDX-1 leads to acinar to ductal 
cell metaplasia in mice14. Overexpression of PDX-1 in cell lines results in 
transformation of non-insulin-producing cells into insulin-producing cells upon 
GLP-1 stimulus15-20. Although PDX-1 is well known as an essential regulator of 
many pancreatic endocrine genes (e.g., insulin1-4, glucokinase21, islet amyloid 
polypeptide22-24, glucose transporter type 2 [GLUT2]25,26, pancreatic polypeptide27 
and somatostatin 6,28), which have critical roles in maintaining glucose 
homeostasis (e.g., insulin and glucokinase), the precise role of PDX-1 in  




Our recent studies demonstrate that PDX-1 is a potential oncogene and a 
therapeutic target for pancreatic neoplasia11,29. It is markedly overexpressed in 
pancreatic cancer8,10,11,30 and regulates proliferation and invasion of human 
pancreatic cancer cells in vitro and in vivo in mice11. PDX-1 over-expressing cells 
have increased tumor formation when implanted in mice29. We have previously 
demonstrated that shRNAhumanPDX-1 lipoplexes effectively ablate human 
pancreatic cancer tumor formation in SCID mice, resulting in prolonged 
survival11.  
In this study, the activity of a novel RNAi effector platform targeting PDX-1 was 
studied in vitro and in vivo in human and mouse cell lines as well as in mouse 
models of progressive pancreatic neoplasia. 
Results 
PDX-1 is overexpressed in human and mouse specimens of progressive 
pancreatic neoplasia  
PDX-1 was overexpressed in 36 human pancreatic neoplasia specimens 
including 26 pancreatic neuroendocrine tumors (Fig. 1a-l) and 10 
nesidioblastosis specimens (Fig. 1m-o), in mouse insulinoma (β TC-6) cells (Fig. 
1p) and in both islets and acinar cells of the pancreas of SSTR1/5-/- mice (Fig. 1r, 
s and t, respectively). These data demonstrate PDX-1 is significantly 
overexpressed in both human and mouse specimens of progressive pancreatic 
neoplasia and are consistent with PDX-1 overexpression as seen in our former 
study of 80 human pancreatic cancer specimens8. 
Bi-shRNAmousePDX-1 knockdown of PDX-1 expression in β TC-6 cells in vitro 
inhibits insulin expression and secretion via inhibition of the insulin 
promoter. 
Bi-shRNAmousePDX-1 resulted in significantly greater knockdown of PDX-1 
expression in β TC-6 cells at doses of 6μg and 12μg per 10-cm dish than 
shRNAmousePDX-1 and empty vector controls in both western blot (Fig. 2a; p<0.05) 
and immunohistochemistry (IHC) analyses (Fig. 2b top panel). Bi-shRNAmousePDX-
1 resulted in significantly greater inhibition of insulin expression (32±3.2% vs 
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62±6.3% vs 93±9.9%) and PDX-1 expression (28±2.7% vs 51±4.5% vs 97±7.3%) 
than that seen with shRNAmousePDX-1 and empty vector control cells, respectively 
(Fig. 2c, p<0.05; and Fig. 2b). Transfection with bi-shRNAmousePDX-1 resulted in 
significantly greater inhibition of glucose-stimulated insulin secretion from β TC-6 
cells in vitro compared to that seen with shRNAmousePDX-1 and empty vector 
controls at glucose concentrations of 5 and 11 mM (p<0.05), respectively (Fig. 
2d). These findings indicate that bi-shRNAmousePDX-1 inhibits insulin expression 
and secretion via PDX-1 knockdown to a greater degree than conventional 
shRNAmousePDX-1 in mouse insulinoma cells.  
To further delineate the mechanism by which knockdown of PDX-1 inhibits 
insulin expression and secretion through reduced activation of rat insulin 
promoter-1(RIP), reporter constructs (RIP-mCherry) with or without 
shRNAmousePDX-1were transfected into β TC-6 cells.  RIP-mCherry-H1-
shRNAmousePDX-1 resulted in significant reduction in mCherry expression as 
compared to that of RIP-mCherry without shRNAmousePDX-1 (10±1.6% vs 35±8.1% 
and 12±2.1% vs 66±13.2% at 24h and 48h, respectively, p<0.05; Fig. 2e). 
Transfection of RIP-mCherry-CMV-eGFP-H1 revealed that 90% of cells were 
successfully transfected, as evidenced by eGFP expression. Additionally, 69% of 
eGFP-expressing cells expressed mCherry, and in RIP-mCherry-CMV-eGFP-H1-
shRNAmousePDX-1 transfected cells, 88% of cells expressed eGFP; however, only 
12% of cells expressed mCherry (p<0.05; Fig. 2f). Decreased PDX-1 expression 
was confirmed using western blot. These data suggest that activation of the 
insulin promoter is significantly inhibited by shRNAmousePDX-1via knockdown of 
PDX-1 expression. 
Species-specific Bi-shRNAPDX-1 knockdown of PDX-1 expression inhibits 
proliferation in mouse insulinoma and human PANC-1 cells. 
Significant suppression of cell proliferation was observed in β TC-6 cells 
transfected with bi-shRNAmousePDX-1. Reductions in cell growth were observed at 
52%, 38%, and 31% in empty vector controls at 24, 48, and 72h post-
transfection, respectively, using MTS assay (Fig. 3a) and at 42%, 35%, and 42% 
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at 12, 24, and 48h post-transfection, respectively, using BrdU incorporation 
assay (Fig. 3b) (p<0.05 at all time points). Bi-shRNAmousePDX-1 resulted in greater 
inhibition of cell proliferation than shRNAmousePDX-1 at low doses (6μg/10-cm dish) 
after 48h of transfection (Fig. 3d).  Cell cycle protein analysis demonstrated 
down-regulation of positive regulators cyclin E, Cdk2, and Cdk4, and up-
regulation of negative regulators p53 and p27, in bi-shRNAmousePDX-1-treated cells 
compared to that of empty vector (p<0.05, respectively; Fig. 3e). Similarly, bi-
shRNAhumanPDX-1 transfection of PANC-1 cells resulted in a reduction of cell 
proliferation by 58%, 40% and 38% of empty vector controls at 24, 48 and 72h 
post-transfection, respectively, with greater inhibition of cell growth than 
shRNAhumanPDX-1 at low doses (6μg or12 μg/10-cm dish)(Fig. 3f, 3g) . These data 
demonstrate that species-specific PDX-1 knockdown inhibits mouse insulinoma 
cell and human pancreatic cancer cell proliferation via alterations in cell cycle 
proteins. 
 
Systemic bi-shRNAmousePDX-1 lipoplexes prevent death from 
hyperinsulinemia and hypoglycemia in an insulinoma SCID mouse model.   
Three cycles of systemic bi-shRNAmousePDX-1 lipoplexes (25μg /mouse biweekly) 
or shRNAmousePDX-1 lipoplexes (35ug /mouse biweekly) prevented death from 
hyperinsulinemia and hypoglycemia (Fig. 4a and b, and c and d, respectively) in 
a lethal insulinoma SCID mouse model. Transient hyperglycemia and 
hypoinsulinemia were observed, but levels returned to baseline on day 150 after 
the initial treatment in both treatment groups. Empty vector lipoplexes had no 
effect on lethal hyperinsulinemia and hypoglycemia, as shown in Fig. 4a and b. 
Overall survival in both treatment groups was significantly longer than that of 
controls (106±7.8d vs 53±1.4d and 146±9.5d vs 53±1.4d, respectively, p<0.05 vs 
controls, Fig. 4f and g, sFig. 1). The difference in survival between the two 
treatment groups was due to intentional sacrificing of that group of mice at an 
earlier time point, but there is no significance (p>0.05)(sFig. 1f). These data 
demonstrate that PDX-1 knockdown using systemic bi-shRNAmousePDX-1 
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lipoplexes effectively prevent hypoglycemic death in an insulinoma SCID mouse 
model.  
Remarkably, systemic bi-shRNAmousePDX-1 and shRNAmousePDX-1 lipoplexes result 
in temporal hyperglycemia, representing a predictable off-target effect in mouse 
islets. After treatment with bi-shRNAmousePDX-1, in situ islet PDX-1 expression was 
reduced in a treatment-dependent manner, from 88±10.1% on day 0 to 71±8.6%, 
49±9.7% and 23±6.6% on days 7, 21, 35 after the initial treatment, respectively, 
and returned to 83±12.4% at the time of sacrifice, as shown in the Fig. 4e, top 
panel. Interestingly, insulin expression also was significantly decreased from 
92±8.3% on day 0 to 61±9.8%, 32±5.3%, 12±1.9% on days 7, 21, 35 after the 
initial treatment, respectively, and returned to 89±15.3% at the time of sacrifice, 
as shown in Fig. 4e, 2nd panel. Expression levels of PP also decreased 
significantly at the same time points after treatment (Fig. 4e, 3rd panel). Markers 
of islet cell proliferation, cell cycle proteins and apoptosis were also studied pre- 
and post-treatment. Islet PCNA expression significantly decreased from 16± 
1.4% to 10±0.8%, 7±0.6%, 5±0.2% and 14±2.0%  on days 0, 7, 21, 35 and upon 
sacrificing, respectively (Fig. 4e, 4th panel). IHC analysis of pancreatic sections 
demonstrated increasing p27 expression and decreasing expression of protein 
levels in cyclin E and Cdk4 on days 0, 7, 21, 35, and upon sacrificing following 
three cycles of treatment (Fig. 4e 5, 6 and 7th panel to top, respectively). This is 
consistent with the findings from western blot analyses of whole pancreata (sFig. 
2). Bi-shRNAmousePDX-1 resulted in a significant increase in apoptosis of mouse 
islets from 1 ±0.2% on day 0, to 14 ±2.4%, 24 ±3.6%, 42±5.5%, 10±1.1% on 
days 7, 21, 35 and upon sacrificing, respectively (Fig 4e bottom panel). Empty 
vector control therapy had no effect on islet PDX-1, insulin, PP expression, cell 
cycle proteins and apoptosis. These data are consistent with findings seen 
following PDX-1 knockdown in mouse insulinoma cells in vitro. They also suggest 
that systemic bi-shRNAPDX-1 lipoplexes result in temporal, mild hyperglycemia 
emanating from suppression of PDX-1 within the islets of Langerhans with 
subsequent suppression of insulin and PP expression, correlating with alterations 
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in islet cell cycle proteins and an increase in islet apoptosis. Expression of all 
islet markers returned to baseline values upon sacrificing, suggesting a 
regenerative capacity of murine islets. Similar patterns of expression of PDX-1, 
insulin, PP, and cell cycle proteins and apoptosis in islet cells also was observed 
after three cycles of shRNAmousePDX-1 lipoplexes (sFig. 3). These data 
demonstrate that systemic bi-shRNAmousePDX-1 lipoplexes effectively prevent 
hypoglycemic death in an insulinoma SCID mouse model and result in in situ 
knockdown of PDX-1 with the islets leading to suppression of insulin expression 
and subsequent hyperglycemia. Remarkably, any off-target islet effects were 
mild and temporal, suggesting a regenerative capacity of the murine endocrine 
pancreas. 
 
Systemic shRNAmousePDX-1 lipoplexes reverse hyperinsulinemia and 
hypoglycemia and alter glucose tolerance in somatostatin receptor 
subtypes 1 and 5 (SSTR1/5-/-) knockout mice  
Three cycles of shRNAmousePDX-1 lipoplexes (35μg /mouse) significantly reversed 
both hyperinsulinemia and hypoglycemia in SSTR1/5-/- mice (3±0.2 μg/l and 
83±19.5mg/dl on day 0 and 0.5±0.1 μg/l and 205±25.9 mg/dl on day 35 after the 
initial treatment, respectively, as seen in Fig. 5a and b). Systemic glucose and 
insulin levels returned to baseline on day 150 after the initial treatment, although 
systemic insulin levels were significantly lower in the treatment group than in 
controls (3.1±0.2 μg/l vs 2±0.6 μg/l, p<0.05). Empty vector lipoplexes were 
without effect on hyperinsulinemia and hypoglycemia (Fig. 5a and b). Islet PDX-1 
expression was reduced in a treatment-dependent manner, from 93±13.5% on 
day 0 to 12±2.6% on day 35 post-treatment; returning to 88±15.2% on day 150 
post-treatment (Fig. 4c, top panel). Islet PCNA expression decreased 
significantly from 33 ±2.8 to 6±0.6% and to 29 ±4.3% on days 0, 35 and 150d 
post-treatment, respectively (Fig. 5c middle panel), which correlated to down-
regulation of cyclin E, cyclin D, Cdk4 and Cdk2. No effect was seen with empty 
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vector controls (p<0.05; Fig. 5d). Increased islet cell apoptosis also was 
observed (1±0.1%, 19±3.2%, 32±5.7%, 58±8.9% and 9±1.4% on days 0, 7, 14, 
35 and 150 post-treatment, respectively, Fig. 5c bottom panel). Intraperitoneal 
glucose tolerance tests (IPGTT) were performed on SSTR1/5-/- mice at day 7 and 
150 after the initial treatment. Fasting glucose levels in the treated group were 
significantly higher than that of controls (117 ± 6.8 mg/dl vs 84 ± 5.9 mg/dl, p < 
0.05), whereas basal insulin levels in the treatment group were lower than those 
of controls (1 ± 0.1μg /l vs 2 ± 0.2 μg/l, p<0.05; Fig 5d). Following intraperitoneal 
glucose injection, systemic glucose levels were significantly higher than those of 
controls at 60 and 240 min post-injection (234 ± 20.2 mg/dl vs 189 ± 21.0 mg/dl 
and 175 ± 11.3 mg/dl vs 137 ± 16.8 mg/dl, respectively p<0.05). Serum insulin 
levels were significantly lower than those of controls at 15 min post-injection (2 ± 
0.1 μg/l vs 3 ± 0.2 μg/l) (Fig. 5e). On post-treatment day 150, no significant 
difference in basal glucose levels was seen between treatment and control 
groups; however, basal insulin levels in the treatment group were significantly 
lower than in those of controls (1 ± 0.3 μg/l vs 2 ± 0.3 μg/l, p<0.05). Only the15-
min time point demonstrated a significant difference in systemic glucose levels 
between the groups (364±60.1 vs 267.0±40.4, p<0.05). Systemic insulin levels; 
however, were significantly lower at the 30- and 120-min time points in the 
treatment group as compared to controls, (2.2± 0.3 μg/l vs 3.3 ± 0.2 μg/l and 2.5 
± 0.1μg/l vs 3.8 ± 0.3μg/l at 30 and 120 min post-injection, respectively; p<0.05) 
(Fig. 5g).  
These data demonstrate that three cycles of systemic shRNAmousePDX-1 lipoplexes 
are well tolerated and effective in reversing hyperinsulinemia and hypoglycemia 
in an immune-competent mouse model of pancreatic neoplasia. Significant 
alterations in glucose tolerance seven days after the initial treatment 
corresponded with suppressed islet PDX-1 and insulin expression. Mild 
alterations in the response to IPGTT seen at 150 days post-treatment correspond 
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with normalization of islet PDX-1 and insulin expression and suggest a 
regenerative capacity of immune-competent murine islets.  
 
Systemic shRNAhumanPDX-1 lipoplexes reduce tumor volume and prolong 
survival in a human pancreatic cancer xenograft SCID mouse model  
PANC-1 cells are human pancreatic cancer cells (PANC-1) that markedly 
overexpress PDX-1, and when placed intraperitoneally, grow large tumors in 
SCID mice. Three cycles of bi-shRNAhumanPDX-1 lipoplexes (35μg/mouse) 
significantly reduced PANC-1 tumor volume with only a few mice having residual 
tumors averaging 50.5 mm3 compared to 100% of control mice with tumors 
averaging 1199 mm3 at 90 days post-treatment, respectively (p<0.05; Fig 6a). 
Survival was significantly longer than controls (115±9.5d vs 85±1.4d, 
respectively; (p=0.001; Fig. 6b) with no significant difference in survival between 
control vector-treated mice and untreated mice (85±9d vs 76±8d, p=0.981). In 
those mice with residual tumors, tumor PDX-1 expression significantly reduced 
from 95±11.1% to 12±1.3% on days 0 and 90 post-treatment, respectively (Fig. 
6c top panel). IHC analysis of residual tumors revealed cell proliferation markers, 
PCNA and Cyclin E, had decreased expression from 84±9.6% and 66±10.2% to 
15±0.8% and to 9±2.3%, respectively (Fig. 6C 2nd and 3rd panels), and an 
increase in P53 expression (Fig 6c, 4th panel). Marked apoptosis was seen in 
residual tumors (Fig. 6c, bottom panel). Remarkably, three cycles of bi-
shRNAhumanPDX-1 lipoplexes had no effect on systemic glucose and insulin levels, 
underscoring the importance of the species-specific design of PDX-1 RNAi (sFig. 
4).   
These data demonstrate that multiple cycles of systemic shRNAhumanPDX-1 
lipoplexes were well tolerated and effectively reduced human pancreatic cancer 
tumor volume and prolonged survival in SCID mice, suggesting a clinical 







This study demonstrates that multiple cycles of a novel RNAi effector platform 
targeting PDX-1 utilizing a systemic DOTAP-Cholesterol delivery vehicle are well-
tolerated and effective in three mouse models of progressive pancreatic 
neoplasia. These findings are consistent with our previous studies that PDX-1 is 
a therapeutic target for pancreatic neoplasia11,29.  Data from the current study 
has demonstrated marked overexpression of PDX-1 in human specimens of 
pancreatic neoplasia. This, combined with our prior findings of PDX-1 expression 
in the most aggressive form of pancreatic neoplasia, pancreatic cancer8, 
supports the clinical application of this novel RNAi platform31.  
 
Our novel RNAi platform was used to knockdown PDX-1 expression in vitro and 
in vivo. Although synthetic small interfering RNAs (siRNAs) are easier to deliver 
in preclinical investigations and have recently entered clinical studies, DNA 
cassettes that express small hairpin RNA (shRNA), microRNA (miRNA), or 
strands of siRNAs have the advantage of prolonged effect32,33. Transcribed 
shRNA from an expression vector intrinsically differs from siRNA with respect to 
intracellular trafficking and nucleotide preference and the bi-shRNA construct can 
further enhance gene knockdown31. Our novel bifunctional RNAi vector 
represses translation of the target mRNA via both cleavage-independent and 
cleavage-dependent RISC loading pathways, resulting in differential Argonaute 
incorporation and separate, but coordinated, target inactivation mechanisms31. 
 
In order to achieve multiple intravenous doses of the RNAi therapy, the liposomal 
delivery system used in this study was developed using 1,2-dioleoyl-3-trimethyl-
ammoniopropane (DOTAP) and cholesterol bilamellar invaginated vesicle (BIV) 
34. BIV envelope the RNAi expression vector creating a lipoplex, which achieve 
low morbidity, effective, and multiple sequential intravenous dose scheduling of 
the RNAi therapeutic34. The composition and structure of these lipoplexes result 
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in an optimized ~5½ hour plasma half-life by minimizing interaction with plasma 
proteins and accumulation in non-target tissues; their fusogenic property avoids 
endocytosis, which otherwise can lead to nucleic acid degradation35. The safety 
of this lipoplex system to be administered intravenously in multiple cycles already 
has been demonstrated in other in vivo models to other targets36,37 and clinical 
trials38,39.  
In a xenograft mouse model of human pancreatic cancer, the most aggressive 
form of pancreatic neoplasia, our strategy of PDX-1 knockdown effectively 
reduced human pancreatic cancer tumor formation in SCID mice and prolonged 
survival11. It was remarkable that in the few mice with residual pancreatic cancer 
tumors, studies of those tumors revealed marked suppression of PDX-1 and 
marked enhancement of both P53 and apoptosis 90 days after therapy. This 
suggests that PDX-1 knockdown activated the apoptotic pathway via P53 within 
PANC-1 cells, similar to in vitro data seen in our previous study as well as that 
seen in insulinoma cell lines in this study. These findings support the concept 
that PDX-1 has oncogenic properties and is a potential therapeutic target for 
pancreatic cancer. We previously reported that 80 human pancreas tissue 
specimens, including liver metastases, had marked overexpression of PDX-
18,11,29. Together, these findings support the development of a phase I clinical 
trial using this novel RNAi platform targeting PDX-1 for treating this devastating 
form of pancreatic neoplasia. Interestingly, there was no adverse effect on islet 
PDX-1 or insulin expression, as well as insulin and glucose levels in mice, 
demonstrating the importance of species-specificity of the PDX-1 shRNA design.  
 
Insulinoma is an intermediate form of pancreatic neoplasia in which tumor 
formation occurs with a ratio of approximately 90% benign and 10% malignant. 
The effect of PDX-1 knockdown on mouse insulinoma cells revealed 1) 
deactivation of an exogenous rat insulin promoter fragment; 2) decreased 
activation of endogenous insulin promoter resulting in inhibition of expression 
and secretion of insulin 3) inhibition of proliferation via alterations on cell cycle 
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proteins, 4) prevention of lethal hypoglycemia in an insulinoma SCID mouse 
model and 5) temporal suppression of islet PDX-1 and insulin expression 
associated with mild hyperglycemia. It is to be noted that due to the rapid 
occurrence of malignant hypoglycemic death, there is insufficient time for 
implanted β TC-6 insulinoma cells to develop into measurable lesions before 
insulinoma-induced hypoglycemic death; therefore, there is no tumor volume to 
be measured in this model. However, the systemic effect of the remarkable 
suppression of in situ islet PDX-1 with associated suppression of insulin and PP, 
both known to regulate glucose homeostasis22-24 and increased islet apoptosis, 
suggests the development of temporal mild hyperglycemia post-therapy is due to 
the effect of bi-shRNAmousePDX-1 lipoplexes on the endocrine pancreas. 
Furthermore, this demonstrates that systemic delivery of the effector platform 
reaches its PDX-1 target. The survival advantage following multiple systemic 
cycles of bi-shRNAmousePDX-1 lipoplexes suggests that mild, transient 
hyperglycemia is an acceptable off-target toxicity in exchange for anti-neoplasia 
activity1-4, 27  
Combined with the finding that 36 human pancreatic neoplasia specimens had 
marked overexpression of PDX-1, these data suggest that our novel RNAi 
effector platform has clinical potential for treating pancreatic neuroendocrine 
tumors, which includes both malignant and benign forms of pancreatic neoplasia, 
as well as nesidioblastosis40. Furthermore, since there are no current effective 
treatments for the devastating hormonal symptoms associated with pancreatic 
neuroendocrine tumors40, this study suggests another potential clinical 
application for the novel RNAi effector platform targeting PDX-1 is the control of 
symptoms associated with excessive hormonal secretion associated with 
pancreatic neoplasia. 
 
Our laboratory has a long history studying the role of somatostatin receptors 
(SSTRs) in islet physiology41-44. We first demonstrated that mouseSSTR5 was 
the SSTR subtype responsible for inhibiting glucose-stimulated insulin secretion 
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from mouse islets and then cloned the mouse SSTR5 gene. SSTR5-/-, beta cell-
specific SSTR5-/- and SSTR1/5-/- mouse models were then generated in our 
laboratory45. Phenotyping of these mice revealed that SSTR1/5-/- mice develop 
basal hypoglycemia, circulating hyperinsulinemia, and are associated with islet 
neoplasia and marked overexpression of islet and acinar PDX-141.    
In these immune-competent mice, multiple cycles of iv shRNAmousePDX-1 
lipoplexes were well tolerated and reversed hyperinsulinemia and hypoglycemia. 
Similar to the results seen in the insulinoma SCID mouse model, SSTR1/5-/- mice 
developed  temporal hyperglycemia associated with suppression of islet PDX-1, 
insulin and PP expression, disruption of cell cycle proteins, and increased islet 
apoptosis. Glucose tolerance tests revealed elevated basal glucose levels, lower 
insulin levels and an abnormal response to IPGTT seven days after the first 
treatment. These results suggest that the hyperglycemia is due to suppression of 
insulin secretion, which would be consistent with suppressed islet PDX-1 and 
insulin expression and enhanced islet apoptosis. Remarkably, these mice have 
almost complete restoration of their response to glucose entolerence associated 
with the normalization of islet PDX-1, insulin, PP and PCNA expression, as well 
as absence of islet apoptosis, suggesting the regenerative capacity of the murine 
endocrine pancreas in this immune-competent mouse model of pancreatic 
neoplasia46-48.  
 
In summary, PDX-1, which exhibits both oncogenic and hormonal-regulatory 
properties, is a therapeutic target in three mouse models of progressive 
pancreatic neoplasia.  Multiple cycles of systemic PDX-1 RNAi lipoplexes were 
well tolerated in both immune-deficient and immune-competent mice. Bi-
shRNAhumanPDX-1 lipoplexes nearly completely ablated human pancreatic cancer 
tumor volume in SCID mice and prolonged survival. Bi-shRNAmousePDX-1 
lipoplexes prevented death from hypoglycemia and hyperinsulinemia in an 
insulinoma mouse model and reversed hyperinsulinemia and hypoglycemia in an 
immune-competent mouse model of pancreatic neoplasia. In these models, 
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murine specific shRNAmousePDX-1 was associated with mild temporal 
hyperglycemia due to suppression of in situ islet PDX-1 expression and related 
islet hormones, as well as enhanced islet apoptosis, demonstrating effective 
systemic delivery of the platform to the PDX-1 target and suggesting 
regenerative capacity for the murine endocrine pancreas following treatment. 
This study demonstrates the potential of a novel RNAi effector platform targeting 




Cell lines, vectors, and antibodies. Mouse β TC-6 and PANC-1 cell lines were 
obtained from the American Type Culture Collection (ATCC, Bethesda, MD. 
Mouse PDX-1 shRNA (shRNAmousePDX-1) was designed as previously described11. 
Bi-functional mouse (bi-shRNAmousePDX-1) and human PDX-1 (bi-shRNAhumanPDX-1) 
was obtained from Gradalis Inc. pRIP-mCherry_CMV-eGFP and pRIP-mCherry 
_CMVeGFP_H1-shRNAmousePDX-1 were subcloned based on the parent vector 
RIP-mCherry-NLS-mCherry which was kindly provided by Dr. Michael Mancini 
from Baylor College of Medicine. Goat anti-rabbit anti-serum and sheep anti-
mouse anti-serum conjugated with horseradish peroxidase were purchased from 
Amersham (Amersham Life Science Inc., Arlington Heights, IL). Rabbit anti-goat 
IgG was obtained from ZYMED (Zymed Laboratories, Inc. South San Francisco, 
CA, USA).  
Transfection and reporter assay. β TC-6 or PANC-1 cells were plated into 10-
cm cell culture plates at 1x106 cells per dish or 24-well plates at 1x105 cells/well 
and incubated at 37°C for 24 h. Transfection assays were performed using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to manusfecture’s 
instruction. Fluorescence signals were observed and counted using fluorescence 
microscopy as previous described11 to determine the reporter activities. 
Cell proliferation assay in vitro. Cell proliferation was determined by MTS 
assay (Promega, Madison, WI) and BrdU incorporate assay (colorimetric) (Roche 
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Diagnosistics GmbH, Mannherim, Germany) at 12, 24, 48 and 72h post 
transfection. Absorbance was read in a Multiskan EX plate reader (Thermo 
Electronic Corp., Franklin, MA) at 492 nm for MTS and 500nm for BrdU assay 
and levels of proliferation were calculated as discribed previously 
Western blot analyses. Forty-eight hours after transfection, as described 
previously11, β TC-6 cells were collected and lysed in RIPA buffer. 20 μg of cell 
lysates were applied to SDS-PAGE gel for electrophoresis. The protein was then 
transferred to membranes to be probed with various antibodies against PDX-1, 
cyclinD1, cyclin E, Cdk2, Cdk4, and p27. Immunocomplexes were visualized by 
enhanced chemiluminescence (ECL) detection using horseradish peroxidase 
conjugated secondary antibodies. 
Animals and shRNA Delivery. SCID mice were housed in a BL-4 facility and 
cared in compliance with the guidelines in The Care and Use of Laboratory 
Animals prepared by the Institute of Laboratory Animal Resources, the 
Commission on Life Science, the National Research Council and the Animal 
Research Committee of Baylor College of Medicine.  DNA Doses were 
determined by meeting the criteria of less than 10% mouse death after injection 
of liposomal shRNA complex in regular SCID mice. Age 8- to 10-week-old male 
mice were inoculated with 1 × 106 β TC-6 or PANC-1 cells per mouse via 
intraperitoneal (ip) injection. Two weeks later, either β TC-6 or PANC-1 mice 
were randomly grouped (30 mice per group) and the first cycle of shRNAmousePDX-
1 or bi-shRNAmousePDX-1or bi-shRNAhumanPDX-1, respectively, were given via tail vein 
injection. The cycles were repeated at days 14 and 28 for a total of three 
injections. The same protocol was applied to SSTR1/5-/- mice using 3 cycles of 
35 μg of shRNAmousePDX-1.shRNAmousePDX-1. The PDX-1 RNAi complexes were 
prepared as previously described11. 
Insulin and glucose measurements. On days 7, 21, 35, and 150 following each 
gene delivery, 50μl whole blood samples were collected and spun to separate 
the serum. Glucose levels were measured using a Beckman-Coulter Glucose 
Analyzer 2 (Coulter-Beckman, Fullerton, CA), and presented as mean ± S.E.M. 
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in mg/dl. Insulin levels were determined using a mouse insulin ELISA kit from 
Mercodia (Linco Research, St. Charles, MO) and presented as mean ± S.E.M. in 
μg /l.  
Intraperitoneal Glucose Tolerance Test (IPGTT)  SSTR1/5-/- mice at days 7 
and 150 after initial delivery of shRNAmousePDX-1 were fasted overnight before 
collection of blood samples as T0. Grouped mice were then given 1.2g 
glucose/kg body weight via ip injection followed by collection of blood samples at 
15, 30, 60, and 120 min after injection of glucose. Glucose and insulin levels 
were measured as described above. 
Necropsy, tissue collection, immunohistochemistry and TUNEL assay 
Pancreatic and tumor tissue sampels were obtained on days 0, 7, 21, 35, and 
end time after initial gene delivery. IHC was performed as described previously. 
Anti- PDX-1, insulin, PP, cyclin E, p27, Cdk4 or PCNA antibodies was applied to 
slides with 1:100 dilution followed by overnight incubation at 4°C. Slides were 
incubated with Cy3 or FITC-conjugated anti-rabbit, goat, or mouse secondary 
antibody depending on derivation of primary antibodies for one hour, and 
mounted with cover slides. TUNEL assay (FragELTM DNA Fragmentation 
Detection Kit, Colorimetric-TdT Enzyme, CALBIOCHEM, La Jolla, CA) was 
performed according to the manufacturer’s protocol. The rate of apoptosis was 
expressed as the ratio of apoptotic cancer cells to the total number of endothelial 
cells in 10 fields at ×100 magnification. 
Statistical Analysis. The unpaired Student’s t-test was used for statistical 
analyses of glucose levels, insulin levels, and cell proliferation with P< 0.05 
indicating significance. The χ2 test was used for rate comparison. Rank-log was 
used for mice survival comparison. Kaplan-Meier in SPSS 15.0 for MS Windows 
was used to plot survival curves. 
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